Phenobarbital Alternatives Compared
| Phenobarbital | Topiramate | Keppra (levetiracetam) |
|
|---|
| Phenobarbital | Topiramate | Keppra (levetiracetam) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Epilepsy, Hyperbilirubinemia, Seizures, Insomnia, Sedation. Phenobarbital may also be used for purposes not listed in this medication guide. |
Prescription only
Topiramate may be prescribed either alone or in combination with other medications for the treatment of certain types of epilepsy, or it may be given for the prevention of migraines. Drowsiness is a... View more |
Prescription only
Keppra is an anticonvulsant that is used in conjunction with other medications for the treatment of certain types of seizures. It may cause drowsiness but it is less likely than some other... View more |
Related suggestions Seizures
Popular comparisons
|
|||||||||||||||||||||||
| More about Phenobarbital | More about Topiramate | More about Keppra (levetiracetam) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Phenobarbital has an average rating of 9.1 out of 10 from a total of 37 ratings on Drugs.com. 92% of reviewers reported a positive effect, while 5% reported a negative effect. |
Topiramate has an average rating of 6.3 out of 10 from a total of 1337 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 28% reported a negative effect. |
Keppra has an average rating of 5.7 out of 10 from a total of 309 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 34% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Phenobarbital side effects |
View all Topiramate side effects |
View all Keppra side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Phenobarbital prices |
View all Topiramate prices |
View all Keppra prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Sezaby | Eprontia, Qudexy XR, Topamax, Trokendi XR | Other levetiracetam brands include: Elepsia XR, Keppra XR, Roweepra, Roweepra XR, Spritam | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
118 hours |
56 hours |
8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 807 drugs are known to interact with Phenobarbital:
|
A total of 291 drugs are known to interact with Topiramate:
|
A total of 239 drugs are known to interact with Keppra:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 24, 1996 |
November 30, 1999 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.